2022
Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients
Friedman DJ, Qin L, Parzynski C, Heist EK, Russo AM, Ranasinghe I, Zeitler EP, Minges KE, Akar JG, Freeman JV, Curtis JP, Al-Khatib SM. Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. Journal Of The American College Of Cardiology 2022, 79: 1050-1059. PMID: 35300816, DOI: 10.1016/j.jacc.2021.12.033.Peer-Reviewed Original ResearchConceptsOlder patientsCause readmissionS-ICDNational Cardiovascular Data Registry ICD RegistryDevice removalTransvenous implantable cardioverter defibrillatorTV-ICD patientsRisk of deathS-ICD patientsService Medicare beneficiariesAnderson-Gill modelsImplantable cardioverter defibrillatorRepresentative national cohortCompeting-risks modelTV-ICDCardiovascular readmissionCause mortalityICD implantationYounger patientsICD RegistryNonfatal outcomesTransvenous ICDAtrial fibrillationNational cohortCardioverter defibrillator
2020
Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
Higgins AY, Annapureddy AR, Wang Y, Minges KE, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy. Journal Of The American Heart Association 2020, 9: e016038. PMID: 32867553, PMCID: PMC7726970, DOI: 10.1161/jaha.120.016038.Peer-Reviewed Original ResearchConceptsImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationNonischemic cardiomyopathyCardiac amyloidosisDiabetes mellitusCerebrovascular diseaseVentricular tachycardiaMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesCox proportional hazards modelPropensity-matched cohortOutcomes of patientsHazards regression modelsProportional hazards modelCause mortalityICD implantationRenal functionMultivariable analysisConclusions MortalityRisk factorsRegistry dataAmyloid cardiomyopathyHigh risk
2019
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation
Loring Z, Shrader P, Allen LA, Blanco R, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Mahaffey KW, Naccarelli GV, Pieper K, Reiffel JA, Singer DE, Steinberg BA, Thomas LE, Peterson ED, Piccini JP. Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal 2019, 219: 21-30. PMID: 31710841, PMCID: PMC7285625, DOI: 10.1016/j.ahj.2019.10.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationCardiovascular DiseasesCause of DeathComorbidityCoronary Artery DiseaseDiabetes MellitusDisease ProgressionEmbolismFemaleGuideline AdherenceHeart FailureHumansHyperlipidemiasHypertensionIntracranial EmbolismMalePeripheral Nervous System DiseasesPeripheral Vascular DiseasesRegistriesSleep Apnea, ObstructiveTreatment OutcomeConceptsGuideline-directed therapyAtrial fibrillationCause mortalityHeart failureAF progressionLower riskNew-onset heart failureObstructive sleep apnea patientsCox proportional hazards modelBetter Informed TreatmentObstructive sleep apneaSleep apnea patientsProportional hazards modelAF patientsDiabetes mellitusNeurovascular eventsClinical outcomesOutcomes RegistrySleep apneaApnea patientsComorbiditiesHazards modelNonsignificant trendPatientsLower mortalityPatterns of amiodarone use and outcomes in clinical practice for atrial fibrillation
Pokorney SD, Holmes DN, Shrader P, Thomas L, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Naccarelli GV, Freeman JV, Singer DE, Washam JB, Peterson ED, Piccini JP, Reiffel JA. Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal 2019, 220: 145-154. PMID: 31812756, DOI: 10.1016/j.ahj.2019.09.017.Peer-Reviewed Original ResearchConceptsUse of amiodaroneAmiodarone useAntiarrhythmic drugsAtrial fibrillationAF patientsDifferent antiarrhythmic drugsGuideline-based indicationsPropensity-matched cohortEffective antiarrhythmic drugProportional hazard modelingORBIT-AF registryLogistic regression modelsHierarchical logistic regressionCause mortalityAF RegistryCardiovascular hospitalizationAmiodaroneHigh incidencePatientsClinical practiceHazard modelingLogistic regressionAdverse effectsRandom interceptFibrillation
2018
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF. Journal Of The American Heart Association 2018, 7: e008928. PMID: 30371218, PMCID: PMC6222961, DOI: 10.1161/jaha.118.008928.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationDabigatranDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRegistriesRenal Insufficiency, ChronicRisk FactorsStrokeTime FactorsTreatment OutcomeWarfarinConceptsBackground Chronic kidney diseaseAntiarrhythmic drug useTransient ischemic attackChronic kidney diseaseAtrial fibrillationAdvanced CKDCKD statusIschemic attackSystemic embolismCause mortalityCreatinine clearanceRhythm controlKidney diseaseDrug useAtrial fibrillation scoreBaseline renal functionOral anticoagulant useRhythm control strategyCox proportional hazardsCKD patientsMajor bleedingOAC useCardiovascular deathCKD stageHigher CHAStroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
Jackson L, Kim S, Fonarow GC, Freeman JV, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Singer D, Thomas L, Blanco R, Peterson ED, Piccini J, Patients and Investigators T. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries. Journal Of The American Heart Association 2018, 7: e008764. PMID: 30369317, PMCID: PMC6201408, DOI: 10.1161/jaha.118.008764.Peer-Reviewed Original ResearchConceptsOral anticoagulationAtrial fibrillationTreatment strategiesCardiology/American Heart Association guidelinesStroke/transient ischemic attackLow CHA2DS2-VASc scoreAmerican Heart Association guidelinesCHA2DS2-VASc scoreThromboembolic event rateTransient ischemic attackHeart Association guidelinesCurrent American CollegePatterns of treatmentIschemic attackVASc scoreCause mortalityStroke riskTreatment patternsAbsolute riskAssociation guidelinesStroke rateVAScAmerican CollegeLower riskPatientsCharacteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation
Durheim MT, Holmes DN, Blanco RG, Allen LA, Chan PS, Freeman JV, Fonarow GC, Go AS, Hylek EM, Mahaffey KW, Pokorney SD, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart 2018, 104: 1850. PMID: 29875139, DOI: 10.1136/heartjnl-2017-312735.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationComorbidityFemaleHealth StatusHeart Conduction SystemHemorrhageHospitalizationHumansLungMalePrevalencePulmonary Disease, Chronic ObstructiveQuality of LifeRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAtrial fibrillationSymptom burdenHeart failurePulmonary diseaseHigh riskDiagnosis of COPDNew-onset heart failureTreatment of AFBeta-blocker useCardiovascular risk factorsMajor bleeding eventsHigh symptom burdenBetter Informed TreatmentCoronary artery diseaseOutcomes of adultsQuality of lifeBleeding eventsDigoxin useBlocker useCause mortalityProspective registryReversible causesCardiovascular mortality
2017
Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry
Kipp R, Hsu JC, Freeman J, Curtis J, Bao H, Hoffmayer KS. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. Heart Rhythm 2017, 15: 847-854. PMID: 28987459, DOI: 10.1016/j.hrthm.2017.09.043.Peer-Reviewed Original ResearchConceptsCause mortalityMedicare beneficiariesICD implantationProcedural complicationsHospital characteristicsMultivariable Cox proportional hazards regression analysisNational Cardiovascular Data Registry ICD RegistryCox proportional hazards regression analysisFirst-time ICD recipientsImplantable cardioverter defibrillator implantationNational Cardiovascular Data RegistryProportional hazards regression analysisKaplan-Meier survival analysisLong-term morbidityPredictors of mortalityCardioverter-defibrillator implantationOccurrence of complicationsRetrospective registry studyAcute procedural complicationsHazards regression analysisLong-term outcomesRisk of mortalityMortality 3 yearsIndex hospitalizationRegistry study
2007
Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test
Dewey FE, Freeman JV, Engel G, Oviedo R, Abrol N, Ahmed N, Myers J, Froelicher VF. Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test. American Heart Journal 2007, 153: 281-288. PMID: 17239690, DOI: 10.1016/j.ahj.2006.11.001.Peer-Reviewed Original ResearchConceptsHeart rate variabilitySquare successive differenceCardiovascular mortalityPrognostic powerHF powerExercise treadmill testingRoot mean square successive differenceFrequency-domain HRV analysisExercise stress testingExercise treadmill testMortality end pointsSuccessive differencesStandard exercise testingHeart rate variability responsesMinutes of recoveryStrongest predictorLow-frequency powerMean square successive differenceHigh-frequency powerR interval dataCardiovascular deathCause mortalityPeak exerciseClinical factorsExercise testing